GERON CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $GERN in the last 7 days.
No SEC Form 4 filings for $GERN in the last 30 days.
See all $GERN insider activity →Geron Corp (GERN) shares rose 14.7% after the company issued its first full-year 2026 RYTELO revenue guidance of $220 million to $240 million. Geron reported Q2 revenue of $57.48 million and a net loss of $16.68 million. For the first half, revenue was $109.32 million with a $20.32 million net loss, alongside discussion of analyst price targets.
Simply Wall St reports Geron (GERN) issued 2026 earnings guidance tied to RYTELO net product revenue and released Q2 and half-year 2026 results on Aug 5. The article cites a $1.48 share price, guidance and updated revenue and net loss figures, and a “fair value” estimate of $3.40 versus $1.48, with a consensus price target of $3.625.
Geron (NASDAQ:GERN) said about 8,000 U.S. patients may be eligible for RYTELO in second-line, lower-risk MDS. The company guided 2026 RYTELO net product revenue to the mid-to-high end of $220 million to $240 million and expects operating expenses of $230 million to $240 million. Q2 gross-to-net deductions rose to 20.7%.
Recent GERN coverage spans earnings, financial news and market movers.
The guidance provides a concrete near-term revenue anchor for RYTELO, likely supporting momentum but keeping the stock highly sensitive to launch execution and cash needs.
Fresh guidance and updated results reframe the valuation debate around RYTELO revenue growth and loss narrowing, with financing risk still highlighted.
The call provides updated full-year revenue positioning plus margin and gross-to-net trajectory, which can drive near-term valuation and trade positioning.
Guidance and quarterly RYTELO demand metrics provide a near-term earnings power check for GERN’s hematology franchise.
RYTELO demand and the updated 2026 revenue range are the core drivers for the move.
alphai scores every news story that mentions GERN with an AI model for sentiment and relevance, and aggregates insider trades from GERON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Geron Corp (GERN) shares rose 14.7% after the company issued its first full-year 2026 RYTELO revenue guidance of $220 million to $240 million. Geron reported Q2 revenue of $57.48 million and a net loss of $16.68 million. For the first half, revenue was $109.32 million with a $20.32 million net loss, alongside discussion of analyst price targets.
6 min readSimply Wall St reports Geron (GERN) issued 2026 earnings guidance tied to RYTELO net product revenue and released Q2 and half-year 2026 results on Aug 5. The article cites a $1.48 share price, guidance and updated revenue and net loss figures, and a “fair value” estimate of $3.40 versus $1.48, with a consensus price target of $3.625.
7 min readGeron (NASDAQ:GERN) said about 8,000 U.S. patients may be eligible for RYTELO in second-line, lower-risk MDS. The company guided 2026 RYTELO net product revenue to the mid-to-high end of $220 million to $240 million and expects operating expenses of $230 million to $240 million. Q2 gross-to-net deductions rose to 20.7%.
6 min readGERON CORP (GERN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product rev
6 min readBiotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readGeron Corporation reported Q2 2026 results on its RYTELO business, citing 17% year-over-year net revenue growth and 24% net revenue growth in the first half of 2026 with total operating expenses down 4%. Full-year 2026 RYTELO net revenue guidance is $220M to $240M. Cash was $327M. Operating expenses guidance is $230M to $240M.
4 min readThe article lists 10 “fastest growing” tech penny stocks under $5, using a Finviz screen for over 50% compounded annual revenue growth in 3 years and recent catalysts. It highlights PowerFleet (NASDAQ:AIOT) launching SafeGuard, reporting up to 83% on-road risk reduction, and approving a $30M repurchase. It also covers Geron (NASDAQ:GERN) granting 690,000 options at $1.23.
7 min readBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Geron ( GERN ) To Contact Him Directly To Discuss Their Options
3 min readFOSTER CITY, Calif., Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- Geron Corporation ( NASDAQ:GERN ) , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's ...
2 min readFour new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations ...
3 min read
